Evidence map›Paper›PMID 37684069›Full record

ReviewSeminars in radiation oncology2023

The Importance of Quality Assurance in Radiation Oncology Clinical Trials.

Thomas J FitzGerald, Maryann Bishop-Jodoin, Fran Laurie, Matthew Iandoli, Koren Smith, Kenneth Ulin, Linda Ding, Janaki Moni, M Giulia Cicchetti, Michael Knopp and 6 more

Abstract readReview
In one paragraph

Review in Seminars in radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Thomas J FitzGeraldDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA.. Electronic address: tj.fitzgerald@umassmemorial.org.
Maryann Bishop-JodoinDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA.
Fran LaurieDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA.
Matthew IandoliDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA.
Koren SmithDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA.
Kenneth UlinDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA.
Linda DingDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA.
Janaki MoniDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA.
M Giulia CicchettiDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA.
Michael KnoppDepartment of Radiology, University of Cincinnati, Cincinnati, OH.
Stephen KryDepartment of Radiation Physics, MD Anderson Cancer Center, Houston, TX.
Ying XiaoDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA.
Mark RosenDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA.
Fred PriorDepartment of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR.
Joel SaltzDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, NY.
Jeff MichalskiDepartment of Radiation Oncology, Washington University in St Louis, St Louis, MO.

Funding

IROC: Enhancing local enrolling site radiological data capture capabilities for NCTN trialsU24CA180803 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI Thomas J. FitzGerald, MICHAEL V KNOPP · 2014 to 2026
$116.2M
NCI NIH HHS U24 CA180803
6 · The paper itself

Abstract

Clinical trials have been the center of progress in modern medicine. In oncology, we are fortunate to have a structure in place through the National Clinical Trials Network (NCTN). The NCTN provides the infrastructure and a forum for scientific discussion to develop clinical concepts for trial design. The NCTN also provides a network group structure to administer trials for successful trial management and outcome analyses. There are many important aspects to trial design and conduct. Modern trials need to ensure appropriate trial conduct and secure data management processes. Of equal importance is the quality assurance of a clinical trial. If progress is to be made in oncology clinical medicine, investigators and patient care providers of service need to feel secure that trial data is complete, accurate, and well-controlled in order to be confident in trial analysis and move trial outcome results into daily practice. As our technology has matured, so has our need to apply technology in a uniform manner for appropriate interpretation of trial outcomes. In this article, we review the importance of quality assurance in clinical trials involving radiation therapy. We will include important aspects of institution and investigator credentialing for participation as well as ongoing processes to ensure that each trial is being managed in a compliant manner. We will provide examples of the importance of complete datasets to ensure study interpretation. We will describe how successful strategies for quality assurance in the past will support new initiatives moving forward.

Indexed as

Clinical Trials as TopicRadiation OncologyData ManagementHumansMedical OncologyRecords

Identifiers

PMID37684069
PMCPMC13623017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.